Tags

Type your tag names separated by a space and hit enter

Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro.
High Alt Med Biol 2010; 11(3):217-22HA

Abstract

We investigated the incidence of AMS amongst a general population of trekkers on Mount Kilimanjaro, using the Lake Louise consensus scoring system (LLS). Additionally we examined the effect of prophylactic acetazolamide and different ascent profiles. Climbers on 3 different ascent itineraries were recruited. At 2743 m we recruited 177 participants (mean age 31, range [18-71]) who completed LLS together with an epidemiological questionnaire. At 4730 m participants (n=189, male=108, female=68, mean age 33, range [1871]) completed LLS, 136 of whom had been followed up from 2730 m. At 2743 m, 3% (5/177) of climbers were AMS positive, and 47% (89/189) of climbers from all itineraries were AMS positive at 4730 m. Of climbers attempting the Marangu itineraries, 33% (45/136) were taking acetazolamide. This group had a similar rate of AMS and no statistical difference in severity of LLS when compared with those not taking prophylactic drugs. We also did not demonstrate a difference between the incidence of AMS in climbers who did or did not take a rest day at 3700 m. However, there was a significant reduction in the incidence of AMS amongst pre-acclimatized subjects. Consistent with previous work, we found that the rate of AMS on Mount Kilimanjaro is high. Furthermore, at these fast ascent rates, there was no evidence of a protective effect of acetazolamide or a single rest day. There is a need to increase public awareness of the risks of altitude sickness and we advocate a pragmatic "golden rules" approach (http://www.altitude.org/altitude_sickness.php).

Authors+Show Affiliations

University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, Scotland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20919888

Citation

Jackson, Stewart J., et al. "Incidence and Predictors of Acute Mountain Sickness Among Trekkers On Mount Kilimanjaro." High Altitude Medicine & Biology, vol. 11, no. 3, 2010, pp. 217-22.
Jackson SJ, Varley J, Sellers C, et al. Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. High Alt Med Biol. 2010;11(3):217-22.
Jackson, S. J., Varley, J., Sellers, C., Josephs, K., Codrington, L., Duke, G., ... Baillie, J. K. (2010). Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. High Altitude Medicine & Biology, 11(3), pp. 217-22. doi:10.1089/ham.2010.1003.
Jackson SJ, et al. Incidence and Predictors of Acute Mountain Sickness Among Trekkers On Mount Kilimanjaro. High Alt Med Biol. 2010;11(3):217-22. PubMed PMID: 20919888.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. AU - Jackson,Stewart J, AU - Varley,James, AU - Sellers,Claudia, AU - Josephs,Katherine, AU - Codrington,Lucy, AU - Duke,Georgina, AU - Njelekela,Marina A, AU - Drummond,Gordon, AU - Sutherland,Andrew I, AU - Thompson,A A Roger, AU - Baillie,J Kenneth, PY - 2010/10/6/entrez PY - 2010/10/6/pubmed PY - 2011/1/21/medline SP - 217 EP - 22 JF - High altitude medicine & biology JO - High Alt. Med. Biol. VL - 11 IS - 3 N2 - We investigated the incidence of AMS amongst a general population of trekkers on Mount Kilimanjaro, using the Lake Louise consensus scoring system (LLS). Additionally we examined the effect of prophylactic acetazolamide and different ascent profiles. Climbers on 3 different ascent itineraries were recruited. At 2743 m we recruited 177 participants (mean age 31, range [18-71]) who completed LLS together with an epidemiological questionnaire. At 4730 m participants (n=189, male=108, female=68, mean age 33, range [1871]) completed LLS, 136 of whom had been followed up from 2730 m. At 2743 m, 3% (5/177) of climbers were AMS positive, and 47% (89/189) of climbers from all itineraries were AMS positive at 4730 m. Of climbers attempting the Marangu itineraries, 33% (45/136) were taking acetazolamide. This group had a similar rate of AMS and no statistical difference in severity of LLS when compared with those not taking prophylactic drugs. We also did not demonstrate a difference between the incidence of AMS in climbers who did or did not take a rest day at 3700 m. However, there was a significant reduction in the incidence of AMS amongst pre-acclimatized subjects. Consistent with previous work, we found that the rate of AMS on Mount Kilimanjaro is high. Furthermore, at these fast ascent rates, there was no evidence of a protective effect of acetazolamide or a single rest day. There is a need to increase public awareness of the risks of altitude sickness and we advocate a pragmatic "golden rules" approach (http://www.altitude.org/altitude_sickness.php). SN - 1557-8682 UR - https://www.unboundmedicine.com/medline/citation/20919888/full_citation L2 - https://www.liebertpub.com/doi/full/10.1089/ham.2010.1003?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -